BenevolentAI S.A.
BAI
ISIN LU2355630455 / Valor 112417726
BenevolentAI S.A.
UMushroom community rating:
About company
BenevolentAI S.A. is a pioneering entity in the intersection of artificial intelligence (AI) and biopharmaceuticals, focusing on the discovery and development of novel drugs. Leveraging its proprietary Benevolent Platform™, the company has successfully built a diverse pipeline of drug candidates. These candidates are distinguished by their potential to become either the best in their class or the first of their kind, indicating a significant emphasis on innovation and addressing unmet medical needs. The use of AI in drug discovery allows BenevolentAI to streamline the research process, potentially reducing the time and cost associated with bringing new therapies to market. While the company's specific therapeutic areas are not detailed in the provided source, the mention of a "rich drug pipeline" suggests a broad focus on developing treatments for a variety of diseases, positioning BenevolentAI at the forefront of technology-driven pharmaceutical research.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (19.09.2025):
BenevolentAI S.A. reported its financial results for the second quarter of 2023, demonstrating significant developments in revenue generation, research and development investments, and strategic partnerships. Despite a decrease in revenue from key collaborations, the company has made substantial progress in its drug discovery pipeline and strengthened its leadership team to drive future growth.
Revenue and Cash Position
For Q2 2023, BenevolentAI reported revenue of £7.3 million (excluding SBP) and maintained a cash and cash equivalents balance of £56.5 million as of 30 June 2023, compared to £130.2 million at the end of December 2022.
Research and Development Investment
The company increased its R&D expenditure to £72.9 million in Q2 2023 from £56.5 million in the previous year, reflecting its ongoing commitment to advancing its drug discovery programs and exploring new therapeutic areas.
Operating Loss
BenevolentAI reported a normalized operating loss of £60.3 million for Q2 2023, a decrease from £65.1 million in the same period last year. The operating loss before changes to working capital was £77.6 million, significantly lower than £197.0 million in Q2 2022.
Strategic Partnerships and Collaborations
The company signed a major deal with Merck KGaA and continued its collaboration with AstraZeneca, despite decreased revenues from the latter. These partnerships are integral to BenevolentAI's strategy to accelerate drug discovery and development.
Leadership and Operational Enhancements
BenevolentAI appointed Dr. Joerg Moeller as CEO and Dr. François Nader as Executive Director. Additionally, Catherine Isted was named Chief Financial Officer and Christina Busmalis as Chief Revenue Officer, strengthening the company’s leadership team to better support its growth initiatives.
Pipeline and Clinical Developments
The company advanced its pipeline assets, including the Phase IIa study results for atopic dermatitis expected in January 2024, and initiated a Phase Ia clinical study for BEN-8744 with topline data expected in Q1 2024. Further, BEN-28010 is on track to be IND-ready by early Q2 2024.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
102 M
Market cap (USD)
Daily traded volume (Shares)
0.423 / 0.38
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
